Based on groups of seven mice in each study arm, mice treated...

Based on groups of seven mice in each study arm, mice treated with PAT-DX1 showed a median survival of 87 days, more than 20% longer than controls (median 72 days). Mean survival data reflected these trends (83 days ± 3.2 days for PAT-DX1 treated mice, 71 days ± 1.2 days for controls). No toxicity associated with DX1 treatments was observed.

20% longer is definitely impressive, and better efficacy may be achieved when the best dosage for mice study is finally determined. In addition, the best part of the ann is "No toxicity associated with DX1 treatments was observed", which means safety is not an issue and thus dosage can be adjusted easily to identify ideal levels for the subsequent in-vivo trials.